The Short Answer

The research on testosterone replacement therapy (TRT) and cancer risk is mixed and still evolving. Some studies show a small increased risk of prostate cancer in men using TRT, while others find no clear link. The risk appears to depend on your age, how long you use TRT, your starting testosterone level, and whether you already have prostate problems. No study has proven that TRT directly causes cancer, but men on TRT do need regular prostate screening.

The most consistent finding across research is that TRT can speed up the growth of existing prostate cancer that has not been detected yet. This is why doctors screen for prostate cancer before starting TRT and monitor patients during treatment. The absolute number of men who develop cancer from TRT remains small, but the risk is real enough that it should factor into your decision.

Key Takeaways

  • Studies show TRT may increase prostate cancer risk slightly, but the evidence is not conclusive and varies depending on the individual and how the therapy is used.
  • TRT can accelerate growth of prostate cancer that already exists but has not been detected, which is why screening before treatment is standard.
  • Your doctor should perform a prostate-specific antigen (PSA) blood test and digital rectal exam before you start TRT to rule out existing cancer.
  • Men on TRT need regular PSA testing and prostate exams during treatment, typically every 6 to 12 months depending on your baseline risk.
  • Other cancers (breast, testicular, liver) show no clear link to TRT in the research, though long-term studies are still limited.

What the Research Actually Shows About Prostate Cancer

The largest and most-cited study on this topic is the Testosterone in Older Men with Mobility Limitations (TTriM) trial, which followed men over several years. It found a higher rate of prostate cancer diagnosis in men using TRT compared to a placebo group. However, researchers debated whether TRT caused the cancer or straightforward made existing cancers easier to detect through PSA testing.

A 2010 meta-analysis in the Journal of Sexual Medicine reviewed multiple studies and found that men on TRT had a higher prostate cancer detection rate, but the absolute increase was small—roughly 1 to 2 additional cases per 1,000 men per year. Importantly, the studies did not show that TRT caused more aggressive cancers or higher death rates from prostate cancer. Men who already had prostate cancer and received TRT did show faster cancer growth, which is why TRT is generally avoided in men with a history of prostate cancer.

More recent research has been reassuring in some ways. A 2021 study in JAMA found no increase in prostate cancer risk in men using testosterone gels, though the study was limited to a shorter follow-up period. The takeaway from the research overall is that the risk exists but is not as dramatic as early studies suggested, and it depends heavily on individual factors like age and baseline PSA levels.

Why Screening Before and During TRT Matters

Before you start TRT, your doctor will order a PSA blood test and usually perform a digital rectal exam (DRE) to check the prostate. These tests look for signs of cancer or benign prostate enlargement. If your PSA is very high or your doctor feels abnormalities during the exam, you may be referred to a urologist for a biopsy before TRT can begin.

The reason for this screening is straightforward: if you already have undetected prostate cancer, adding testosterone can make it grow faster. Catching cancer early—or ruling it out—before you start therapy reduces this risk. If your baseline PSA is normal and your exam is clear, the risk of TRT triggering cancer is much lower, though not zero.

During TRT, you will need repeat PSA tests and prostate exams. The frequency depends on your age, your baseline PSA level, and your family history. Men over 50 with a normal baseline PSA typically get tested every 6 to 12 months. If your PSA starts rising faster than expected, your doctor may pause TRT and refer you to a urologist to investigate.

Who Is at Higher Risk on TRT

Your personal risk of prostate cancer on TRT is not the same as everyone else's. Men over 65, men with a family history of prostate cancer, and Black men (who have higher baseline prostate cancer risk) should have more detailed conversations with their doctor about whether TRT is right for them. These groups may need more frequent screening or may be steered toward lower doses or shorter treatment periods.

Men with a history of benign prostate hyperplasia (BPH)—enlarged prostate—also face a higher risk of complications on TRT, though not necessarily cancer. TRT can worsen urinary symptoms like difficulty urinating or frequent nighttime trips to the bathroom. If you have BPH symptoms, your doctor may recommend treating that first or choosing a different approach to address low testosterone.

Conversely, younger men (under 50) with no family history and normal baseline PSA have a lower absolute risk. This does not mean zero risk, but the research shows the danger is concentrated in older men and those with other risk factors.

Other Cancers and TRT

The concern about TRT and cancer is almost entirely focused on the prostate because testosterone fuels prostate cell growth. Other cancers—breast cancer, testicular cancer, liver cancer—have not shown a clear link to TRT in the available research. Breast cancer in men is rare and does not appear to increase with TRT use. Testicular cancer is also not associated with TRT in the literature.

Liver cancer is a theoretical concern because the liver processes hormones, but studies have not found a real increase in liver cancer risk from TRT. Men with existing liver disease may still need to avoid TRT or use it cautiously, but this is more about how their liver handles the hormone than about cancer risk.

What Happens If Your PSA Rises During TRT

A rising PSA during TRT does not automatically mean you have cancer. PSA can go up for several reasons: the testosterone itself may be raising it, you may have a urinary tract infection, or you may have benign prostate enlargement. Your doctor will look at how fast the PSA is rising and whether it has crossed certain thresholds.

If your PSA rises more than 1.4 nanograms per milliliter (ng/mL) in a year, or if it reaches 4 ng/mL or higher, your doctor will typically refer you to a urologist. The urologist may recommend a biopsy to check for cancer, or they may recommend pausing TRT to see if the PSA stabilizes. Some men pause TRT temporarily, recheck their PSA, and then restart at a lower dose.

The key is not to panic if your PSA goes up slightly. Many men on TRT have modest PSA increases that never turn into cancer. Regular monitoring catches problems early, which is when treatment is most effective.

Weighing the Risk Against the Benefits

The decision to use TRT is a personal one that involves weighing the documented benefits—improved energy, mood, sexual function, and muscle mass—against the risks, including the small but real increased prostate cancer risk. Men with severe symptoms of low testosterone and no risk factors for prostate cancer often decide the benefits outweigh the risks. Men with a strong family history of prostate cancer or existing prostate problems may decide differently.

Your doctor can help you understand your individual risk profile. If you are a good candidate for TRT based on screening, you can reduce your cancer risk further by using the lowest effective dose, having regular PSA monitoring, and being honest about any urinary symptoms or family history. Some men also choose to use TRT for a limited time—say, two to three years—rather than indefinitely, though the long-term safety of this approach is not yet clear.

Frequently Asked Questions

Does testosterone replacement definitely cause prostate cancer?

No. The research shows a possible increased risk, but it is not proven that TRT directly causes cancer. Some studies suggest TRT speeds up the growth of cancer that already exists but has not been detected. This is why screening before treatment is so important.

What PSA level is too high to start testosterone replacement?

There is no single cutoff, but most doctors become cautious if your baseline PSA is above 4 ng/mL or if it has been rising quickly. A urologist may recommend a biopsy before you start TRT if your PSA is elevated. Your doctor will discuss your individual situation with you.

How often do I need prostate screening while on testosterone replacement?

Most men need a PSA test and prostate exam every 6 to 12 months while on TRT. The exact schedule depends on your age, baseline PSA, and risk factors. Your doctor will set a schedule based on your profile and adjust it if your PSA starts rising faster than expected.

Can I use testosterone replacement if I have a family history of prostate cancer?

A family history of prostate cancer does not automatically disqualify you from TRT, but it does mean you need more careful screening and monitoring. Talk with your doctor about your specific family history—whether relatives were diagnosed young, whether they died from the cancer, and how many relatives were affected. This helps your doctor assess your personal risk.

What should I do if my PSA goes up while I am on testosterone replacement?

Tell your doctor right away. A single elevated PSA does not mean cancer, but your doctor will want to repeat the test and may refer you to a urologist if the rise is significant. Your doctor may recommend pausing TRT temporarily, lowering your dose, or investigating further with imaging or a biopsy.